Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540192 | 1.00 | NFE2L2 (0.55) | NFE2L2PRMT1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL5537600 | 0.86 | NFE2L2 (0.51) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL5537597 | 0.86 | NFE2L2 (0.51) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL2096373 | 0.82 | NFE2L2 (0.57) | NFE2L2PRMT1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2096371 | 0.82 | NFE2L2 (0.57) | NFE2L2PRMT1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL5537244 | 0.81 | ABCG2 (0.45) | NFE2L2CYP1A1CYP1A2CYP1B1MAPT | |
| SCHEMBL5537246 | 0.81 | ABCG2 (0.45) | NFE2L2CYP1A1CYP1A2CYP1B1MAPT | |
| SCHEMBL2089318 | 0.80 | NFE2L2 (0.55) | NFE2L2PRMT1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2089319 | 0.80 | NFE2L2 (0.55) | NFE2L2PRMT1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2094815 | 0.80 | NFE2L2 (0.62) | NFE2L2PRMT1CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NFE2L2 846/4885PRMT1 645/4885CYP1A1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.